Cardio-Obstetrics
Definition
Cardio-obstetrics (also called the "pregnancy heart team") is a multidisciplinary clinical model integrating cardiology with obstetric specialties to manage cardiovascular disease (CVD) during pregnancy, delivery, and up to 1 year postpartum. CVD is the leading cause of pregnancy-related mortality in the United States, rising from 7.2 to 17.2 deaths per 100,000 live births between 1987 and 2015. Preconception counseling, antepartum monitoring, peripartum management, and postpartum cardiovascular follow-up are all within the scope of the cardio-obstetrics team.
Key Concepts
Team Composition and Scope of Care
- The cardio-obstetrics team typically includes: obstetricians, cardiologists, anesthesiologists, maternal-fetal medicine (MFM) specialists, geneticists, neurologists, nurses, and pharmacists sources/cv-pregnancy-aha-2020 (rating: high)
- Scope spans the full reproductive care continuum: preconception → antepartum → peripartum → postpartum → up to 1 year postpartum
- Team jointly develops a comprehensive management strategy including expected events, shared decision-making, medication safety review, and delivery planning
Preconception Counseling
- Essential for all women with preexisting CVD or history of preeclampsia prior to subsequent pregnancy
- Core elements: individual maternal CV risk estimation, medication review (ACEi/ARBs are teratogenic — must be replaced before pregnancy), folic acid assessment, nutritional status, contraception counseling sources/cv-pregnancy-aha-2020 (rating: high)
- Early identification of prohibitive-risk conditions allows informed shared decision-making
Maternal Risk Stratification — Modified WHO Classification
- The modified WHO classification is the only prospectively validated method for estimating individual maternal cardiovascular risk in women with CVD contemplating pregnancy sources/cv-pregnancy-aha-2020 (rating: high); sources/cv-pregnancy-esc-2018 (rating: very high)
- Other risk models have been developed but none are prospectively validated
- All validated models include: prior CVD event, history of arrhythmia, prior heart failure, poor functional class, resting cyanosis, anticoagulant use, mechanical valve
- NT-proBNP >128 pg/mL at 20 weeks gestation is an independent predictor of later cardiac events sources/cv-pregnancy-esc-2018
- Prohibitive/highest-risk conditions (mWHO Class IV — pregnancy contraindicated, 40–100% event rate):
- Pulmonary arterial hypertension (PAH) of any cause
- Severe systemic ventricular dysfunction (LVEF <30% or NYHA III–IV)
- Prior PPCM with any residual LV impairment (even mild dysfunction)
- Severe mitral stenosis (valve area <1.0 cm²) or severe symptomatic aortic stenosis
- Systemic right ventricle with moderate/severe dysfunction (Mustard/Senning TGA or congenitally corrected TGA)
- Severe aortic dilatation (>45 mm Marfan/Loeys-Dietz; >50 mm BAV)
- Vascular Ehlers-Danlos syndrome; severe re-coarctation
- Fontan circulation with any complication (SaO₂ <85%, depressed ventricular function, moderate-severe AV regurgitation, refractory arrhythmia, protein-losing enteropathy)
- See concepts/mWHO-Classification for full class definitions and event rates
Antepartum Monitoring
- Frequency of monitoring and team composition determined by modified WHO risk class sources/cv-pregnancy-aha-2020 (rating: high)
- Echo assessment of aortic dimensions in aortopathy: every 12 weeks (low risk) or monthly (high risk)
- Hemodynamic and structural changes in pregnancy must be accounted for when interpreting imaging results (e.g., physiological increases in valve velocities)
Delivery Planning
- Vaginal delivery preferred for most women with heart disease; cesarean reserved for obstetric indications or specific cardiovascular circumstances (e.g., fully anticoagulated with VKA at labor) sources/cv-pregnancy-aha-2020 (rating: high)
- ACOG recommends elective induction 39–40 weeks for cardiac disease patients without spontaneous onset
- WHO Class IV decisions made on a case-by-case basis by the high-risk team
Postpartum Care and Contraception
- Peripartum admission is the ideal time for: future pregnancy discussion, contraception planning, late CVD risk counseling sources/cv-pregnancy-aha-2020 (rating: high)
- IUD (copper or hormonal) and progestin-only subdermal implants can be placed immediately postpartum
- Combined hormonal contraception (CHC) unreasonable (risk outweighs benefit) in: DVT/PE history, hypertension with vascular disease, PPCM (including mild systolic dysfunction), complicated valvular disease, ischemic heart disease
- Patients with APOs warrant fourth-trimester follow-up with aggressive risk factor modification; APOs are CVD risk-enhancing conditions per the 2018 multisociety cholesterol guideline
Specific Conditions Requiring Cardio-Obstetrics Team
| Condition | Key Consideration |
|---|---|
| PPCM | Bromocriptine adjunctive; prognosis by EF; contraception before discharge |
| HCM | 23% HF/arrhythmia risk; avoid diuretics aggressively (need preload); myosin inhibitors contraindicated — myectomy before conception if LVOTO indicated |
| Mechanical valves | Warfarin ≤5 mg/d or LMWH (anti-Xa 0.8–1.2); DOACs avoided |
| Aortopathy | WHO III–IV; echo every 12 weeks to monthly; β-blockers |
| LQTS | β-blockade throughout pregnancy; high postpartum risk |
| PAH | WHO Class IV; pregnancy often discouraged |
| Ischemic heart disease | SCAD: conservative management; atherosclerotic STEMI: PCI |
Arrhythmia-Specific Cardio-Obstetrics Framework (HRS 2023)
The 2023 HRS Consensus defines the "cardio-obstetrics team" as including — for arrhythmia management — a cardiac electrophysiologist, MFM subspecialist, anesthesiologist, neonatologist, and pediatric cardiologist/electrophysiologist (for fetal arrhythmias) sources/arrhythmia-pregnancy-hrs-2023 (rating: very high)
Arrhythmia triage requiring immediate cardio-obstetrics involvement:
- Hemodynamically significant sustained tachyarrhythmia (SVT, AF/AFL, VT) requiring cardioversion or antiarrhythmic infusion
- Maternal cardiac arrest (perimortem C-section within 5 minutes if viable fetus, at site of arrest)
- Fetal incessant tachyarrhythmia (SVT >50% of time; AFL with hydrops)
- Any inherited arrhythmia syndrome (IAS) in pregnancy — delivery planning, risk stratification
- Complex catheter ablation during pregnancy (preparation for urgent delivery) sources/arrhythmia-pregnancy-hrs-2023
IAS-specific delivery planning (three-tier framework):
| Risk Level | Criteria | Management |
|---|---|---|
| Low | No prior events; QTc ≤470 ms | Standard cardiology consultation |
| Medium | Remote events or QTc ≥470 ms | Tertiary centre; IV line; external defibrillator |
| High | Arrhythmic syncope/CA/sustained VA within 1 year on therapy | Cardiac theatre; arterial line; IV antiarrhythmics; telemetry |
Genetic Cardiomyopathy — the Preconception Pathway
Carrying a cardiomyopathy variant changes the shape of cardio-obstetric care in three ways that a mWHO class alone does not capture (sources/cmp-pregnancy-jaccadv-2026, rating: medium):
- The decision moves earlier. Reproductive options — PGT-M with IVF, prenatal diagnosis, or accepting the 50% transmission risk — are only available before conception. A referral at 20 weeks has already closed most of them.
- The medication conversion is a procedure, not a prescription. ACE inhibitors, ARBs, MRAs, SGLT2 inhibitors, ivabradine and vericiguat must all be stopped and replaced with beta-blockers, hydralazine and nitrates — and the switch itself can cause reflex hypertension or decompensation. Symptomatic or severely affected patients may need admission to do it safely.
- Device decisions are made before pregnancy or not at all. An ICD indicated for secondary prevention in ACM should be implanted preconception; the same decision made at 24 weeks carries additional procedural and fetal risk.
- The postpartum window is a separate risk period, not the tail of the pregnancy. Most PPCM presents in the first postpartum month; ACM shows its highest ventricular arrhythmia risk there (HR 13.74 in the NORDIC ARVC Register); and it is the point at which GDMT is restarted around lactation goals.
| Genetic phenotype | Preconception action | mWHO |
|---|---|---|
| ACM | Assess for secondary-prevention ICD; stop nothing, continue beta-blockade | II–III |
| HCM | Myectomy if LVOTO indicated; stop myosin inhibitor | II–III |
| DCM | Convert GDMT; document pre-pregnancy LVEF (the strongest single predictor) | III (LVEF 30–45%), IV (<30%) |
| PPCM | Genetic counselling and testing for all; define recovery before another pregnancy | IV if any residual dysfunction |
| GP/PN | Baseline ECG, Holter, echo; plan by phenotype, not genotype | Not assigned |
See concepts/Pregnancy-in-Genetic-Cardiomyopathy for the full account, including PGT-M eligibility and the surveillance schedule.
Contradictions / Open Questions
- Whether referral to dedicated cardio-obstetrics centres improves hard maternal/fetal outcomes over general obstetric care is not established — most evidence is observational sources/cv-pregnancy-aha-2020 (rating: high)
- Optimal timing and frequency of antepartum monitoring for lower-risk (WHO Class I–II) conditions is not defined by RCT data
- Postpartum follow-up duration (beyond 6 weeks) is not standardized; fourth-trimester (12-week) protocols vary by institution
- The team model is recommended for a group whose risk no score can measure. Genotype-positive/phenotype-negative women are assigned no mWHO class at all, yet are the fastest-growing referral group — guidance for them is extrapolated from variant-specific cohorts of 10–30 patients, and the recommendation to convene a Pregnancy Heart Team is made precisely because the risk tools cannot rank them. (sources/cmp-pregnancy-jaccadv-2026, rating: medium)
- Aspirin for preeclampsia prevention is recommended across cardiomyopathy and explicitly unstudied in the group that now makes up most preconception referrals — genotype-positive women without a phenotype. (sources/cmp-pregnancy-jaccadv-2026)
Connections
- Related to entities/Peripartum-Cardiomyopathy — PPCM is the cardiomyopathy most specifically managed by the cardio-obstetrics team
- Related to concepts/Hypertensive-Disorders-of-Pregnancy — HDP team management; postpartum BP surveillance
- Related to concepts/Preeclampsia — preeclampsia requires immediate cardio-obstetrics involvement
- Related to concepts/Adverse-Pregnancy-Outcomes — APOs mandate fourth-trimester CVD risk follow-up
- Related to concepts/LQTS-Pregnancy-Management — LQTS-specific arrhythmia risk in pregnancy and postpartum
- Related to entities/Maternal-Health-Disparities — racial/ethnic mortality disparities in maternal CVD
- Related to entities/Hypertension — antihypertensive management in pregnancy and postpartum
- Related to concepts/Pregnancy-in-Genetic-Cardiomyopathy — the genetic cardiomyopathy pathway
- Related to concepts/Arrhythmia-in-Pregnancy — comprehensive arrhythmia management framework (HRS 2023)
- Related to concepts/Fetal-Arrhythmia — fetal arrhythmia team coordination